---
firstreceived_date: February 22, 2005
is_fda_regulated: 
reference: []
overall_contact_backup: {}
completion_date:
  attributes:
    type: Actual
  value: January 2007
responsible_party: {}
firstreceived_results_date: 
is_section_801: 
detailed_description: {}
link: []
has_expanded_access: 'No'
id: NCT00104078
intervention:
- intervention_name: MYO-029
  other_name: []
  description: 
  arm_group_label: []
  intervention_type: Drug
source: Wyeth is now a wholly owned subsidiary of Pfizer
eligibility:
  gender: Both
  maximum_age: N/A
  sampling_method: 
  minimum_age: 18 Years
  study_pop: {}
  criteria:
    textblock: |-
      Inclusion Criteria:

                -  Written informed consent.

                -  Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD),
                   Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy
                   (LGMD)

                -  Independently ambulatory

              Exclusion Criteria:

                -  Patients with certain clinical conditions

                -  Patients using steroids or other medications with the potential to affect muscle
                   function

                -  History of sensitivity to monoclonal antibodies or protein pharmaceuticals

                -  Pregnant or lactating women.
  healthy_volunteers: 'No'
removed_countries: {}
other_outcome: []
primary_completion_date: {}
last_injected: '2015-07-13T23:13:19.109Z'
intervention_browse: {}
target_duration: 
number_of_arms: 
start_date: February 2005
why_stopped: 
id_info:
  org_study_id: 3147K2-101
  secondary_id: []
  nct_alias: []
  nct_id: NCT00104078
acronym: 
arm_group: []
sponsors:
  collaborator: []
  lead_sponsor:
    agency: Wyeth is now a wholly owned subsidiary of Pfizer
    agency_class: Industry
secondary_outcome: []
study_type: Interventional
biospec_retention: 
overall_status: Completed
primary_outcome:
- safety_issue: 
  time_frame: 
  description: 
  measure: Safety assessment
overall_official:
- first_name: 
  last_name: Medical Monitor, MD
  middle_name: 
  affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
  degrees: 
  role: Study Director
phase: Phase 1/Phase 2
location_countries:
  country:
  - United States
condition:
- Becker Muscular Dystrophy
- Facioscapulohumeral Muscular Dystrophy
- Limb-Girdle Muscular Dystrophy
clinical_results: {}
study_design: 'Allocation: Randomized, Endpoint Classification: Safety Study, Intervention
  Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment'
keyword: []
results_reference: []
oversight_info:
  has_dmc: 
  authority:
  - 'United States: Food and Drug Administration'
number_of_groups: 
location:
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: Washington
      state: District of Columbia
      zip: '20010'
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 38.895
    formatted: Washington, DC, USA
    longitude: -77.036
    original: Washington, District of Columbia
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: Kansas City
      state: Kansas
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 39.114
    formatted: Kansas City, KS, USA
    longitude: -94.627
    original: Kansas City, Kansas
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: Baltimore
      state: Maryland
      zip: 21287-7519
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 39.29
    formatted: Baltimore, MD, USA
    longitude: -76.612
    original: Baltimore, Maryland
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: Boston
      state: Massachusetts
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 42.358
    formatted: Boston, MA, USA
    longitude: -71.06
    original: Boston, Massachusetts
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: St. Louis
      state: Missouri
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 38.627
    formatted: St Louis, MO, USA
    longitude: -90.199
    original: St. Louis, Missouri
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: Rochester
      state: New York
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 43.161
    formatted: Rochester, NY, USA
    longitude: -77.611
    original: Rochester, New York
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: Columbus
      state: Ohio
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 39.961
    formatted: Columbus, OH, USA
    longitude: -82.999
    original: Columbus, Ohio
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: Dallas
      state: Texas
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 32.803
    formatted: Dallas, TX, USA
    longitude: -96.77
    original: Dallas, Texas
- status: 
  contact_backup: {}
  facility:
    name: 
    address:
      city: Salt Lake City
      state: Utah
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 40.761
    formatted: Salt Lake City, UT, USA
    longitude: -111.891
    original: Salt Lake City, Utah
official_title: 
verification_date: December 2007
required_header:
  url: https://clinicaltrials.gov/show/NCT00104078
  link_text: Link to the current ClinicalTrials.gov record.
overall_contact: {}
brief_title: Study Evaluating MYO-029 in Adult Muscular Dystrophy
biospec_descr: {}
condition_browse:
  mesh_term:
  - Muscular Dystrophies
  - Muscular Dystrophies, Limb-Girdle
  - Muscular Dystrophy, Duchenne
  - Muscular Dystrophy, Facioscapulohumeral
brief_summary:
  textblock: |-
    The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult
          patients with muscular dystrophy.
enrollment:
  attributes:
    type: 
  value: '108'
lastchanged_date: December 19, 2007
